News & Updates
Filter by Specialty:
Cemiplimab improves 5-year survival in advanced NSCLC
First-line cemiplimab monotherapy continues to provide durable overall (OS) and progression-free survival (PFS) benefits at 5 years compared with chemotherapy in advanced nonsmall cell lung cancer (NSCLC) patients with PD-L1 expression ≥50 percent, according to the results of the EMPOWER-Lung 1 study presented at WCLC 2024.
Cemiplimab improves 5-year survival in advanced NSCLC
08 Oct 2024
Physical activity, SBP tied to thoracic aortic size
Hard physical activity and normotensive individuals and increasing systolic blood pressure (SBP) in those with hypertension each correlate with larger thoracic aortic size, suggests a study.
Physical activity, SBP tied to thoracic aortic size
08 Oct 2024
Viral meningitis may induce developmental delays in kids
A mild developmental delay may occur following an infection of viral meningitis in preschool children, according to a study, noting that targeted follow-up must be considered.
Viral meningitis may induce developmental delays in kids
08 Oct 2024
Osimertinib after CRT safe, effective in unresectable stage III EGFR-mutated NSCLC
Treatment with osimertinib following definitive chemoradiotherapy (CRT) demonstrates a manageable safety profile in patients with unresectable stage III EGFR-mutated nonsmall cell lung cancer (NSCLC), reports a study presented at WCLC 2024.